BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Moderna

Novavax

Pfizer

Vaxart

Here's Some Good News for Vaccine Stock Investors

Why Moderna, Pfizer, and Other Vaccine Stocks Dropped Today

Johnson & Johnson

The FDA is trying to make available a safe and effective COVID-19 vaccine for use in children below 12 years of age as soon as possible.

Will COVID-19 Vaccines for Children be Available by Year-End?

Coronavirus vaccine stocks Pfizer Inc. (NYSE: PFE), Moderna, Inc. (NASDAQ: MRNA), BioNTech SE (NASDAQ: BNTX) and Novavax, Inc. (NASDAQ: NVAX) were trading notably lower Monday. What Happened: A new review authored by a group of international scientists and published by the Lancet suggeststhat booster doses of the COVID-19 vaccine may not be currently needed for the general population.

Why Moderna, BioNTech, Novavax And Pfizer Are Trading Lower

Apple

Alibaba

Dynavax Technologies

iShares MSCI Emerging Markets ETF

KraneShares CSI China Internet ETF

iShares MSCI China ETF

Netflix

NetEase

NXP Semiconductors

Invesco QQQ

SPDR S&P 500 ETF Trust

Valneva SE

Chinese regulators continue to apply pressure on the country's biggest tech companies, this time reportedly looking to split up Alibaba (NYSE:BABA) founder Jack Ma's Alipay. Beijing is pushing for Alipay to create a separate app for its loan business.

China Crackdown Continues

This past Thursday, the Biden administration unveiled a new vaccine mandate. It demands that private employers with more than 100 workers require their staff to be vaccinated or conduct weekly tests for COVID-19.

The Best Biotech for Booster Season

American Airlines

Alaska Air Group

Delta Air Lines

JetBlue Airways

Southwest Airlines

United Continental Hlds

Stocks like Delta (DAL), American Airlines (AAL) and Southwest (LUV) gain on Thursday despite the Delta variant-induced dull warnings.

Why U.S. Airline Stocks Gained Yesterday Despite Dim Views

BioNTech SE (NASDAQ: BNTX) is reportedly prepping a launch for its mRNA-based COVID-19 vaccine developed with Pfizer Inc (NYSE: PFE) for children between 5 and 11 years old. Also read:   Pfizer/BioNTech Initiates COVID-19 Vaccine Trial In Children Below 12 Years.

BioNTech Prepares To Launch COVID-19 Shot For 5 to11 Year Old: Reuters

The vaccine makers are almost ready to seek approval for the jab's use among children as young as five years old.

Pfizer-BioNTech To Seek Approval For First Covid Vaccine For Young Children ‘In Next Few Weeks'

It's been a changing story about the details of the U.S. plan for booster shots.

Will There Be 6-Month or 8-Month COVID Boosters?

Merck

AT&T

T-Mobile US

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Finding stocks that pay a decent dividend is a little more difficult in the current market than it has been in the past. The strong bull market combined with difficult economic conditions means that stock prices have skyrocketed, but dividend payments have not followed suit.

5 High-Dividend Stocks That Gurus Are Buying

European Medical Agency (EMA) has approved additional manufacturing sites to produce Comirnaty, the COVID-19 vaccine developed by Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX). One site, located in Frankfurt, is operated by Sanofi-Aventis Deutschland GmbH, part of Sanofi SA (NASDAQ: SNY).

EMA Gives Nod To Additional Sites For Pfizer - BioNTech COVID-19 Vaccine

Pfizer and BioNTech shared huge commercial success with their Comirnaty COVID-19 vaccine. Despite that, BioNTech stock has significantly outperformed Pfizer stock, befuddling Pfizer's investors as its stock struggled to keep pace with BioNTech stock.

Pfizer Vs. BioNTech Stock: Which Is The Better Buy?

Carrier Global

Capital One

Alphabet

Goldman Sachs

Nucor

Thomson Reuters

U.S. economic news hasn't been too consistent since the delta variant took hold, but these large-cap stocks are steady long-term choices. The post 7 of the Best Large-Cap Stocks to Buy Now appeared first on InvestorPlace.

7 of the Best Large-Cap Stocks to Buy Now

The Pfizer-BioNTech shot will likely be the only COVID-19 vaccine booster available by Sept. 20, the Biden administration's target date to begin offering them, but Dr. Anthony Fauci said Sunday that Moderna's shot shouldn't be too far behind.

Pfizer booster likely to be OK'd by Sept. 20, but Moderna's may lag, Fauci says

On Sunday, President Joe Biden's Chief Medical Adviser Dr. Anthony Fauci said officials would soon get the regulatory clearance to administer Covid-19 vaccine booster shots made by Pfizer Inc (NYSE: PFE). However, the Moderna Inc (NASDAQ: MRNA) booster could take a little longer.

Moderna Boosters Might Not Be Ready By Sept 20, Pfizer On Track: Fauci

Dr. Anthony Fauci said third Pfizer vaccine doses will likely be ready by Sept. 20, but approval for a Moderna booster may be delayed.

Pfizer Covid booster shots will likely be ready Sept. 20, but Moderna may be delayed, Fauci says

Did the FDA Move Too Slowly in Fully Approving the Pfizer-BioNTech Vaccine?

There are two key reasons why vaccine stocks won't get a boost from mandates.

Why Vaccine Mandates Won't Drive Pfizer, BioNTech, and Moderna Stocks Higher

There are differences of opinion on this hot-button topic.

Are COVID Vaccine Mandates Justified Based on the Data?

If so, we might live through 2020 all over again.

This Could Mean Moderna and BioNTech Are Actually Dirt Cheap

The FDA's panel of outside vaccine advisors will meet in two weeks and discuss Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) supplemental application for a booster shot of their COVID-19 vaccine. The Advisory Committee Meeting is scheduled on September 17, just three days before the Biden administration said it would roll out boosters.

FDA Schedules Adcomm For Pfizer/BioNTech's COVID-19 Booster Shot

The FDA plans to convene an outside advisory committee to consider whether to authorize a booster dose of Pfizer's Covid-19 vaccine, raising further questions about the White House's assurance that booster doses will be widely available later this month.

FDA Will Convene Advisory Committee to Consider Pfizer Covid-19 Booster

There's more good news on the way for these two coronavirus vaccine developers.

These 2 Unstoppable Stocks Just Got a Shot in the Arm

TAOYUAN, Taiwan (Reuters) -The first batch of BioNTech SE's COVID-19 vaccine arrived in Taiwan on Thursday, helped by the involvement of two of the world's most important tech firms after months of heated political and diplomatic wrangling. Taiwan has blamed China, which claims the island as its own territory, for nixing an original order from the German firm this year - charges Beijing has angrily denied.

Helped by TSMC and Foxconn, BioNTech vaccines finally reach Taiwan

News for BioNTech SE Stock (BNTX)